Catalyst Wire Dossier Catalyst Wire Dossier

Veligrotug

VRDN 001 · Viridian Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Veligrotug, covering 2025-07-18 to 2026-08-13. Get the full timeline:

Most recent: Clinical Trial Results: A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) [Phase 3]

See pricing